# Phase 2 Burkitt Lymphoma trials recruiting: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Burkitt Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Burkitt Lymphoma trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/burkitt-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| June 23, 2026 | NCT07662928 | Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study | AIDS Malignancy Consortium | Phase 2 | Recruiting | Adult Burkitt Lymphoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662928) |
| June 9, 2026 | NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More... | SWOG Cancer Research Network | Phase 2 | Not yet recruiting | Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636564) |
| May 4, 2026 | NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564453) |
| July 31, 2025 | NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment... | University of Washington | Phase 2 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07097363) |
| April 9, 2025 | NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia... | City of Hope Medical Center | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06918431) |
| March 6, 2025 | NCT06861348 | Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Leukemia, Lymphocytic, Acute | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861348) |
| January 15, 2025 | NCT06777264 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Acute Lymphoblastic Leukemia, B Cell ALL | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06777264) |
| September 23, 2024 | NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608732) |
| May 1, 2024 | NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393985) |
| March 19, 2024 | NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06317662) |
| December 22, 2023 | NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | Beijing Yongtai Ruike Biotechnology Company Ltd | Phase 2 | Recruiting | Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06179524) |
| November 22, 2023 | NCT06144606 | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Recruiting | B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06144606) |
| November 9, 2023 | NCT06124157 | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young... | National Cancer Institute (NCI) | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06124157) |
| October 13, 2023 | NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | Beijing Tongren Hospital | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06081478) |
| April 10, 2023 | NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia... | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05805605) |
| December 13, 2022 | NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | KK Women's and Children's Hospital | Phase 2 | Recruiting | Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult, B-cell Acute... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05648019) |
| March 16, 2022 | NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | Sponsor not shown (see the record) | Phase 2 | Recruiting | B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05281809) |
| October 19, 2021 | NCT05082519 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Sponsor not shown (see the record) | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Obesity | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05082519) |
| February 9, 2021 | NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | Medical College of Wisconsin | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04746209) |
| September 14, 2020 | NCT04546399 | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | 461 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04546399) |
| December 12, 2019 | NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04195633) |
| November 14, 2018 | NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory... | National Cancer Institute (NCI) | Phase 2 | Recruiting | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03739814) |
| April 27, 2018 | NCT03509961 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Pediatric Transplantation & Cellular Therapy Consortium | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03509961) |
| October 19, 2017 | NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03314974) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Masonic Cancer Center, University of Minnesota | 2 |
| M.D. Anderson Cancer Center | 2 |
| The First Affiliated Hospital of Soochow University | 2 |
| First Affiliated Hospital of Zhejiang University | 2 |
| Fred Hutchinson Cancer Center | 2 |
| University of Washington | 1 |
| City of Hope Medical Center | 1 |
| KK Women's and Children's Hospital | 1 |
| Beijing Yongtai Ruike Biotechnology Company Ltd | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| New York Medical College | 1 |
| SWOG Cancer Research Network | 1 |
| AIDS Malignancy Consortium | 1 |
| Beijing Tongren Hospital | 1 |
| Medical College of Wisconsin | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Pediatric Transplantation & Cellular Therapy Consortium | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 19 |
| China | 6 |
| Puerto Rico | 4 |
| Australia | 2 |
| Canada | 2 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cardiology practices in the United States](https://specstream.ai/data/businesses/cardiology-practices/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Theme restaurants in the United States](https://specstream.ai/data/businesses/theme-restaurants/united-states)
- [Public schools in the United States](https://specstream.ai/data/businesses/public-schools/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
